ArticlePLoS pathogens2011
A family of helminth molecules that modulate innate cell responses via molecular mimicry of host antimicrobial peptides.
Article in PLoS pathogens, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
71 citing papers in PubMed, 145 citations in OpenAlex.
- CRISPR/Cas genome editing, functional genomics, and diagnostics for parasitic helminths.International journal for parasitology · 2025Review
- An immunoregulatory amphipathic peptide derived from Fasciola hepatica helminth defense molecule (FhHDM-1.C2) exhibits potent biotherapeutic activity in a murine model of multiple sclerosis.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025Article
- The Calicophoron daubneyi genome provides new insight into mechanisms of feeding, eggshell synthesis and parasite-microbe interactions.BMC biology · 2025Article
- Cecropin anisaxin-2S hasFrontiers in immunology · 2025Article
- CRISPR-based functional genomics for schistosomes and related flatworms.Trends in parasitology · 2024Review
- Association of Antibodies to Helminth Defense Molecule 1 With Inflammation, Organomegaly, and Decreased Nutritional Status in Schistosomiasis Japonica.The Journal of infectious diseases · 2024Article
- Article
- The Parasite-Derived Peptide, FhHDM-1, Selectively Modulates miRNA Expression inJournal of diabetes research · 2024Article
- Trematode Genomics and Proteomics.Advances in experimental medicine and biology · 2024Article
- Exploring extracellular vesicles in zoonotic helminth biology: implications for diagnosis, therapeutic and delivery.Frontiers in cellular and infection microbiology · 2024Review
- Parasite manipulation of host phenotypes inferred from transcriptional analyses in a trematode-amphipod system.Molecular ecology · 2023Article
- Antigens from the HelminthInternational journal of molecular sciences · 2023Article
- Type I Cystatin Derived fromPathogens (Basel, Switzerland) · 2023Article
- The helminth derived peptide FhHDM-1 redirects macrophage metabolism towards glutaminolysis to regulate the pro-inflammatory response.Frontiers in immunology · 2023Article
- Exploring the role of macrophages in determining the pathogenesis of liver fluke infection.Parasitology · 2022Review
- Molecular Characteristics and Potent Immunomodulatory Activity of Fasciola hepatica Cystatin.The Korean journal of parasitology · 2022Article
- Targeting the PI3K/Akt signaling pathway in pancreatic β-cells to enhance their survival and function: An emerging therapeutic strategy for type 1 diabetes.Journal of diabetes · 2022Review
- The Zoonotic Helminth ParasiteAnimals : an open access journal from MDPI · 2021Article
- Pathogenicity and virulence of the liver flukesVirulence · 2021Article
- The parasite-derived peptide FhHDM-1 activates the PI3K/Akt pathway to prevent cytokine-induced apoptosis of β-cells.Journal of molecular medicine (Berlin, Germany) · 2021Article
11 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
Abstract
Over the last decade a significant number of studies have highlighted the central role of host antimicrobial (or defence) peptides in modulating the response of innate immune cells to pathogen-associated ligands. In humans, the most widely studied antimicrobial peptide is LL-37, a 37-residue peptide containing an amphipathic helix that is released via proteolytic cleavage of the precursor protein CAP18. Owing to its ability to protect against lethal endotoxaemia and clinically-relevant bacterial infections, LL-37 and its derivatives are seen as attractive candidates for anti-sepsis therapies. We have identified a novel family of molecules secreted by parasitic helminths (helminth defence molecules; HDMs) that exhibit similar biochemical and functional characteristics to human defence peptides, particularly CAP18. The HDM secreted by Fasciola hepatica (FhHDM-1) adopts a predominantly α-helical structure in solution. Processing of FhHDM-1 by F. hepatica cathepsin L1 releases a 34-residue C-terminal fragment containing a conserved amphipathic helix. This is analogous to the proteolytic processing of CAP18 to release LL-37, which modulates innate cell activation by classical toll-like receptor (TLR) ligands such as lipopolysaccharide (LPS). We show that full-length recombinant FhHDM-1 and a peptide analogue of the amphipathic C-terminus bind directly to LPS in a concentration-dependent manner, reducing its interaction with both LPS-binding protein (LBP) and the surface of macrophages. Furthermore, FhHDM-1 and the amphipathic C-terminal peptide protect mice against LPS-induced inflammation by significantly reducing the release of inflammatory mediators from macrophages. We propose that HDMs, by mimicking the function of host defence peptides, represent a novel family of innate cell modulators with therapeutic potential in anti-sepsis treatments and prevention of inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.